Universal ambitions

How Emergex aims to create universal vaccines for viral epidemics

Emergex Vaccines Holdings Ltd. is making synthetic peptide vaccines it thinks could provide universal immunity -- and at a fraction of the time and cost of traditional vaccine development.

Emergex launched in 2016 with IP acquired from Immunotope Inc. covering the discovery of viral peptides that are immunogenic and highly conserved between members of a genus.

It also exclusively licensed gold nanoparticle technology from Midatech Pharma plc., which it

Read the full 670 word article

How to gain access

Continue reading with a
two-week free trial.